[go: up one dir, main page]

AU5498100A - Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions - Google Patents

Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions

Info

Publication number
AU5498100A
AU5498100A AU54981/00A AU5498100A AU5498100A AU 5498100 A AU5498100 A AU 5498100A AU 54981/00 A AU54981/00 A AU 54981/00A AU 5498100 A AU5498100 A AU 5498100A AU 5498100 A AU5498100 A AU 5498100A
Authority
AU
Australia
Prior art keywords
compositions
chemotherapy
tumor cells
resistant tumor
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54981/00A
Inventor
Paul Actor
George Tuszynski
Taffy Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5498100A publication Critical patent/AU5498100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU54981/00A 1999-06-21 2000-06-21 Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions Abandoned AU5498100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14031099P 1999-06-21 1999-06-21
US60140310 1999-06-21
PCT/US2000/016955 WO2000078359A2 (en) 1999-06-21 2000-06-21 Compositions for treating chemotherapy-resistant tumor cells

Publications (1)

Publication Number Publication Date
AU5498100A true AU5498100A (en) 2001-01-09

Family

ID=22490672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54981/00A Abandoned AU5498100A (en) 1999-06-21 2000-06-21 Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions

Country Status (2)

Country Link
AU (1) AU5498100A (en)
WO (1) WO2000078359A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478543A1 (en) 2001-10-26 2003-04-26 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
EP1069137A1 (en) * 1990-09-24 2001-01-17 W.R. Grace & Co.-Conn. Peptides having thrombospondin-like activity and their therapeutic use
WO1992017499A1 (en) * 1991-04-08 1992-10-15 Cornell Research Foundation, Inc. A unique hexapeptide derived from thrombospondin and its uses
US5770563A (en) * 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
US5367059A (en) * 1992-05-14 1994-11-22 W. R. Grace & Co.-Conn. Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor
AU723614B2 (en) * 1997-02-13 2000-08-31 Bausch & Lomb Surgical, Inc. Method for destroying retinal pigment epithelial cells
EA200100264A1 (en) * 1999-06-21 2001-10-22 Филадельфия Хеалс Энд Эдьюкейшн Корпорейшн ANGIOCIDIN: AN ADHESIVE CELL TUMOR RECEPTOR SPECIFIC FOR CYS-SER-VAL-THR-CYS-GLY

Also Published As

Publication number Publication date
WO2000078359A3 (en) 2002-01-24
WO2000078359A2 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU5481000A (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitor
AU2003243373A1 (en) Cell migration inhibiting compositions and methods and compositions for treating cancer
EP1176964B8 (en) Uses of et743 for treating cancer
MXPA02010866A (en) Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy.
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
AU7360000A (en) Methods and compositions for preventing and treating prostate disorders
AU2001245987A1 (en) Compositions and methods for gene therapy
AU4033900A (en) Compositions and methods for treating cell proliferation disorders
AU4823599A (en) Prostate cancer-associated genes
AU2002308522A1 (en) Methods for inhibiting tumor cell proliferation
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU1916501A (en) Oncolytic combinations for the treatment of cancer
AU8026300A (en) Sodd gene expression in cancer
AU1917101A (en) Oncolytic combinations for the treatment of cancer
AU1595001A (en) Oncolytic combinations for the treatment of cancer
AU2001278068A1 (en) Methods and compositions for predicting prostate cancer
AU5498100A (en) Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase